Eli Lilly and Stock Forecast for 2022 - 2025 - 2030
Updated on 09/26/2022
Eli Lilly and Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $350.00. If it reached this goal, it would represent a potential upside of approximately 12.37% from the previous closing price in September, 2022. The high end is $412.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
12.37% Upside
Eli Lilly and 2022 - 2025 - 2030 için Gerçeğe Uygun Değer Tahmini
Eli Lilly and's Price has seen growth In the last three years, going from $118.22 to $173.81 – a gain of 47.03% In the next year, analysts believe that Fair Value will reach $184.67 – an increase of 6.25%. For the next nine years, the forecast is forFair Value to grow by 148.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$166.72 | $185.23 | 9.17% |
| ROG Stock Forecast | Roche Holding | Outperform |
18
|
CHF309.30 | CHF384.23 | 21.24% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$143.06 | $164.23 | 9.05% |
| MRK Stock Forecast | Merck | Outperform |
6
|
$86.78 | $99.57 | 15.23% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
18
|
$520.79 | $658.24 | 29.61% |
Eli Lilly and 2022 - 2025 - 2030 Gelir Tahmini
Eli Lilly and's Revenue has seen growth In the last three years, going from $21.49B to $28.32B – a gain of 31.75% In the next year, analysts believe that Revenue will reach $28.51B – an increase of 0.66%. For the next nine years, the forecast is forRevenue to grow by 69.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$100.68 | $128.88 | 25.15% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£100.16 | £136.08 | 42.14% |
| NOVN Stock Forecast | Novartis | Hold |
18
|
CHF74.36 | CHF103.75 | 21.68% |
Hisse Başına Temettü Tahmini 2022 - 2025 - 2030
In the last three years, Dividend per Share for Eli Lilly and has grown by 51.11%, going from $2.25 to $3.40. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $3.78 – an increase of 11.18%. Over the next nine years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 252.65%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$70.71 | $79.05 | 17.38% |
| AMGN Stock Forecast | Amgen | Hold |
9
|
$226.97 | $246.51 | 12.35% |
| SAN Stock Forecast | Sanofi | Outperform |
18
|
78.81€ | 104.66€ | 40.21% |
Eli Lilly and 2022 - 2025 - 2030 için Serbest Nakit Akışı Tahmini
In the last three years, Eli Lilly and's Free Cash Flow has increased by 37.95%, going from $4.31B to $5.95B. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $7.76B – an increase of 30.41%. The Eli Lilly and forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
16
|
$278.14 | $228.01 | -19.88% |
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$62.86 | $69.65 | 12.95% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$697.33 | $696.64 | 8.70% |
Eli Lilly and 2022 - 2025 - 2030 için Net Gelir Tahmini
Eli Lilly and's Net Income has grown in the last three years, jumping from $3.23B to $5.58B – an increase of 72.70%. In the next year, analysts predict that Net Income will reach $7.88B – an increase of 41.25%. For the next nine years, the forecast is for Net Income to grow by 211.18%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$150.05 | $235.45 | 49.95% |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
18
|
159.00€ | 147.51€ | 32.08% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$233.92 | $278.08 | 19.70% |
Eli Lilly and 2022 - 2025 - 2030 için FAVÖK Tahmini
In the last three years, Eli Lilly and's EBITDA has grown, increasing from $7.63B to $9.73B – an increase of 27.38%. For next year, the 12 analysts predict EBITDA of $10.44B, which would mean an increase of 7.30%. Over the next nine years, the pros' prediction is EBITDAof $20.45B, which would mean a nine-year growth forecast of 110.29%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£13.13 | £16.08 | 43.95% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
49.58€ | 67.79€ | 60.35% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥3.79k | ¥0.00 | 16.13% |
2022 - 2025 - 2030 için FVÖK Tahmini
Eli Lilly and's EBIT has increased by 35.71% In the last three years, going from $6.03B to $8.18B. In the next year, analysts expect EBIT to reach $9.13B – an increase of 11.70%. For the next nine years, the forecast is for EBIT to grow by 143.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.40k | ¥0.00 | 32.24% |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$197.78 | $242.78 | 15.03% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$55.41 | $69.92 | 24.53% |
Eli Lilly and EPS Fiyat Tahmini 2022 - 2025 - 2030 yılları arası tahmini
Eli Lilly and's EPS has seen growth In the last three years, going from $5.55 to $8.16 – a gain of 47.03% In the next year, analysts believe that EPS will reach $8.67 – an increase of 6.25%. For the next nine years, the forecast is forEPS to grow by 148.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.90k | ¥0.00 | 26.02% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$200.78 | $209.00 | 19.28% |
| 4507 Stock Forecast | Shionogi & | Outperform |
18
|
¥6.85k | ¥0.00 | 28.18% |